《艾昆纬：2023年6-8月季度药品市场展望报告（英文版）（74页）.pdf》由会员分享，可在线阅读，更多相关《艾昆纬：2023年6-8月季度药品市场展望报告（英文版）（74页）.pdf（74页珍藏版）》请在三个皮匠报告上搜索。

1、 2023.All rights reserved.IQVIAis a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.Quarterly Report:August 2023Data Month Ending:June 2023IQVIA Quarterly Pharmaceutical Market OutlookEuropean Thought Leadership1+Global Adult Vaccination Trends+D

2、eep Dive into COVID-19 Vaccination+Channel Preference Survey 2023 Results+New Active Substance,plus Innovative Launch Analysis+Medicine Demand and Supply+Engagement with Health Care Professionals+AppendixIQVIA Quarterly Pharmaceutical Market Outlook2Global Adult Vaccination Trends3Impact of COVID-19

3、 on global adult vaccination dosesGlobal adult vaccinations show steady progression for 2013-2020,then declined between 2020-2022 due to COVID-19 pandemicIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Note:Adult vaccinations include Influenza,Td/TdaP,Hepatitis B,Herpes zoster,Pneumococcal

4、vaccines;Source:1IQVIA Institute Report 2023Abbreviation:Td-diphtheria and tetanus;TdaP-diphtheria,tetanus and pertussis;VPD-Vaccine-preventable diseases 11912815217120321723229526524753585053535252454445211718161516251917162232302833181717171719142016201412201335120152017153222020201820191220221020

5、2111256275221244304349400363151515+8%+9%PneumococcalInfluenzaHerpes zosterHepatitis BTd/TdaPGlobal adult vaccination doses(M),2013-20221Vaccine-preventable diseases(VPDs)may present serious burden on the public healthcare system in terms of treatment cost and may also increase the risk of other co-m

6、orbidities such as cardiovascular,cerebrovascular,neurological,renal complications etc.In the EU,VPD causes estimated 94,000 deaths annually with a significant number of hospitalizations1In 2013-2020,the number of adult vaccination doses grew at a CAGR of 9%(221 M in 2013 to 400 M in 2020),whereas i

7、n 2020-2022,the number of doses reduced 12%(400 M in 2020 to 351 M in 2022)In 2021-2022,globally received vaccination doses for other VPDs are16.2 doses/100 adults,in contrast to global COVID-19 vaccination of 132 doses/100 adults(2022)excluding booster dosesAmong other vaccines,the number of Influe

8、nza vaccine doses increased continuously in between 2013-2020,but reduced significantly in between 2020-20221 The disruption in immunization services and economic loss due to COVID-19 possibly resulted in sudden decline in adult vaccination doses Adverse effects presented in the form of missed adult

9、 vaccination doses require more focus and in-depth analysis4Missed doses and spend of adult vaccinationGlobally 100 M adult vaccination doses are missed,although the adult vaccination spend has moderately increased in EuropeIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Note:Adult vaccinat

10、ions include Influenza,Td/TdaP,Hepatitis B,Herpes zoster,Pneumococcal vaccines;Source:1IQVIA Institute Report 2023;2Eurostat 2023Abbreviation:Td-diphtheria and tetanus;TdaP-diphtheria,tetanus and pertussis400363351408404428202020212022400320340360380420440365380387ActualTrendline 2(2013-2020)Trendli

11、ne 1(2013-2019)Adult vaccination spend in EU4&UK as a share of total pharmaceutical expenditure(2023)0.3%0.4%1.7%0.7%0.1%ItalyUKFranceGermanySpainEstimated adult vaccine missed doses in 2021 and 20220.4%0.3%0.3%0.3%0.4%0.4%0.4%0.6%0.6%0.7%2013202020152017 20182014201620192021 2022Adult vaccination s

12、pend in Europe as a share of total pharmaceutical expenditure(2013-2022)The estimated number of missed adult vaccine doses are 100 M between 2021-2022 for Influenza,Td/TdaP,Hepatitis B,Herpes zoster and Pneumococcal(as per the derivation from the mid-point of two historical trend lines for the perio

13、ds,2013-2019 and 2013-2020 respectively)In Europe,the adult vaccination expenses show a moderate increase of 0.2%-0.3%of total pharmaceutical expenditure over time(2013-2022)EU4&UK countries show substantial variations in adult vaccination spend with Germany spending the maximum share(1.7%)and Spain

14、 spending the minimum(0.1%)as a share of total pharmaceutical expenditure(2023)Increasing proportion of elderly individuals(65 years)among adult populations in Europe requires additional investments for adult vaccinations1,2 Other than infectious disease prevention,adult vaccinations lead to avoidan

15、ce of long-term co-morbidity risks,hospitalizations and premature deaths,and provides extensive individual,social and economic benefits,particularly in elderly adults1,25Strategies to overcome declination in adult vaccinationImproved access,increased awareness and routine follow-up may help to recov

16、er adult vaccination programsIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Source:1IQVIA Institute Report 2023;2EIA2030;3Vaccines Europe 2022;4The Adult Immunization Board 2023;Abbreviation:VPD vaccine preventable disease COVID-19 pandemic resulted in substantial decline on routine vaccin

17、ation programs in adults,which impacted the overall health,quality of life and mortality in adults Establishment of regulatory policies and improvement of vaccination strategies are necessary for improving coverage rates and the protection of adults,especially elderly population and adults with co-m

18、orbidities Possible approaches to expand adult vaccinationEU/National initiatives for adult vaccination recoveryAdult vaccination as a standard of care:Ensuring appropriate financing for the implementation of accessible vaccination programs with a focus on preventionImproved accessibility to vaccina

19、tion programs:Increasing the number of vaccinators(e.g.,including pharmacists)and creating additional access points for vaccination facilities supported by laws and regulations Monitoring progress and follow-up:Capturing,analyzing and reporting vaccination data to track progress and enable follow-up

20、 along with improving the availability of digital data infrastructure Increased awareness among citizens:Providing support,encouragement and incentives to the HCPs to have routine conversations about vaccination with the patients.Raising media and public awareness about the consequences of infectiou

21、s diseases and the importance of adult vaccination may also be beneficial1The European Immunization Agenda 2030(EIA2030)Implementation of the experiences gained during COVID-19 in strengthening the vaccination of older adults or adults with co-morbidities throughout the life courseExploring and esta

22、blishing collaborations within and outside the health sector to promote the life course approaches,such as maternal health services,occupational health,social care services for older adults etc.Expansion and diversification of vaccination pathways including vaccination during pregnancy,in health wor

23、kers and in older adults.2Four action plans for prioritizing adult vaccinationTo prioritize and incorporate adult vaccination in national immunization plansIncrease awareness and education among citizens,patients and HCPs on the consequences of VPDs and the benefits of adult vaccinationsExtending th

24、e scope of vaccination by HCPs,pharmacies,workplaces etc.Establishing and expanding E-vaccination cards,national digitalized registries for adult vaccination including reminder and recall system for improved effects3Reduce the impact of VPDs in European adultsProvide evidence-based guidance on funda

25、mental technical and strategic issuesMonitor the progress of adult vaccination programs4The Adult Immunization Board(AIB)6Deep Dive into COVID-19 Vaccination7Top 10 countries Total vaccinations(Total number of COVID-19 vaccination doses administered,M)By August 2023,more than 13 billion vaccines hav

26、e been administered globallyIQVIA Quarterly Pharmaceutical Market Outlook-August 20233,491.12,206.7676.7486.4447.6383.7361.5339.9266.5223.24,585.813,469.301,00010,0002,0007,0005,0009,0003,0006,0004,0008,00011,00012,00013,00014,000US (9th May)Japan(7th May)China(9th Feb)Mexico(7th Oct)OthersIndonesia

27、(6th Jun)India(12th Aug)Brazil(22nd Mar)Bangladesh(12th Aug)Pakistan(6th Aug)Vietnam(30th Jun)WorldSources:IQVIA European Thought Leadership,31/08/2023.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldI

28、nData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/20238There are more than one type of COVID vaccine approved,even in the least vaccinated countriesIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Sources:IQVIA European Thought Leadership,31/08/2023.Vaccine rollout data

29、:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023.Excludes Eritrea,Marshall Islands,Micronesia and the Vatican which have not reported vaccine do

30、ses in OWID.PNG=Papua New Guinea,DRC=The Democratic Republic of the CongoBottom 10 reporting countries Vaccine doses per 100 people0.323.815.737.2710.4113.9617.1717.8619.0023.01175.23169.744002010705030608090100110120130140150160170180Cameroon(23rd Jul)Congo(31st Jul)DRC(4th Jun)Burundi(23rd Jul)Yem

31、en(20th Jun)Haiti(2nd Jun)PNG(1st May)Madagascar(16th Jul)Senegal(23rd Jul)Syria(18th Apr)Other(Avg)World(Avg)9Across the EU4&UK,on average more than two doses have been administered per personIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Sources:IQVIA European Thought Leadership 31/08/20

32、23.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023.Vaccine approval data:https:/COVID19.trackvaccines.org/vaccines/,https:/

33、 per person are inclusive of all age groups10Bottom ten countries by absolute number of fully vaccinated people,represent a mix of low to lower-middle income countriesMajority of the bottom 10 reporting countries are from Africa,in terms of proportion of population vaccinatedIQVIA Quarterly Pharmace

34、utical Market Outlook-August 202323.625.727.030.731.636.338.539.053.555.020 2545040535105,159,515301550SKN(2nd Dec)San Marino(22nd May)*Monaco(21st Dec)Burundi(14th May)Saint Lucia(2nd Dec)Other(Sum)World(Sum)5,159,510.2Grenada(17th Mar)Greenland(14th Mar)5,159,149.3Andorra(21st May)Dominica(7th Oct

35、)SVG(31st Mar)Bottom 10 countries Fully vaccinated people(Thousands)Bottom 10 countries Share of population fully vaccinated(%)Graphs represents the number/share that have received all doses prescribed by the vaccination protocolIndividuals are counted if they have received one dose of a vaccine wit

36、h a one dose protocol or two doses of a vaccine with a two dose protocolData is only available for countries which report the breakdown of doses administered by first and second doses0.282.363.023.178.688.8410.6610.7810.9611.2766.3265.02200155302510403545 50 55 60 65 70Gabon(5th Feb)World(Avg)Senega

37、l(23rd Jul)Burundi(14th May)Yemen(20th Jun)Haiti(2nd Jun)PNG(1st May)Madagascar(16th Jul)Syria(18th Apr)Congo(31st Jul)Cameroon(23rd Jul)Other(Avg)Sources:IQVIA European Thought Leadership,31/08/2023 analysis of data provided on the OurWorldinData.org website.Vaccine rollout data:Max Roser,Hannah Ri

38、tchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023.Notes:SKN=St.Kitts and Nevis,SVG=St Vincent and the Grenadines,PNG=Papua New Guinea;*denotes year 2021Excludes Erit

39、rea,Marshall Islands,Micronesia,the Vatican,Liechtenstein and Switzerland which have not reported fully vaccinated people in OWID11While high population countries dominate absolute numbers of fully vaccinated people,small-mid sized nations dominate doses per personIQVIA Quarterly Pharmaceutical Mark

40、et Outlook-August 2023807003.54.010204090100 110 120 1304.53.02.01.52.560ChilePopulation(millions)QatarCubaBruneiJapanCambodiaTaiwanPortugalVietnamPeruDoses per person01/2190007/2301/202007/2001/23007/211,10001/2207/221,3001002003004001,0005008006007001,200Fully vaccinated individuals(millions)Indon

41、esiaChinaIndiaJapanBrazilUnited StatesBangladeshPakistanVietnamMexicoGraphs represent the number/share that have received all initial doses prescribed by the vaccination protocolIndividuals are counted if they have received one dose of a vaccine with a one dose initial protocol,two doses of an initi

42、al two dose protocol,etc.Data is only available for countries which report the breakdown of doses administeredChina begins reportingSource:IQVIA European Thought Leadership,31/08/2023 analysis of data provided on the OurWorldinData.org website.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Or

43、tiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023Top 10 countries by number of doses per person12In the EU4&UK,on average 79%of the population is fully vaccinated;Spain is leading w

44、ith 86%of individuals fully vaccinated IQVIA Quarterly Pharmaceutical Market Outlook-August 2023Sources:IQVIA European Thought Leadership,31/08/2023.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInDa

45、ta.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/202313Top 10 countries by booster doses and the countries with the highest share of omicron cases sequenced illustrates how the variant spread globally in a short period of timeAmong EU nations,Belgium,Sweden and Italy are in the t

46、op ten countries administering the maximum number of booster shots per hundred peopleIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Booster doses are doses administered beyond those prescribed by the original vaccination protocol for example a 3rddose of the Comirnaty vaccine141.7140.2106.

47、499.893.291.190.887.281.180.9Bhutan(30th Oct)Taiwan(16th Jul)Japan(6th May)Chile(7th Feb)Sweden(19th Mar)Belgium(25th May)Uruguay(14th Dec)Malta(1st Aug)Peru(4th Aug)Italy(30th Jun)80.0%60.0%50.0%50.0%50.0%46.0%27.7%25.0%22.5%22.2%20.0%40.0%50.0%50.0%50.0%54.0%72.3%75.0%77.5%77.8%GuatemalaArgentinaE

48、cuadorNetherlandsMexicoBrazilPuerto RicoSint MaartenAustriaSpainOmicron(XBB.1.5+XBB.1.5.*)Other variantsNote that Variants of Concern may be overrepresented,as suspected cases are likely to be sequenced preferentially or faster than other casesSource:IQVIA European Thought Leadership 31/08/2023.Boos

49、ter shot rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023.*Excludes results with 100%of sequenced cases as omicron,as these countrie

50、s likely only sent omicron cases to be sequenced and confirmed,as at 16/08/2023 https:/www.gisaid.org/hcov19-variants/Booster doses per hundred peopleTop 10 countries by highest share of sequenced cases of omicron in the past four weeks*14Vaccination and booster dose strategies adopted by countriesI

51、QVIA Quarterly Pharmaceutical Market Outlook-August 2023Spain Ministry of Health declares the end of health crisis caused by COVID-19 and continues its work to establish appropriate recommendation for COVID-19 vaccination and to integrate it into national vaccination programs(July 2023)5As per the r

52、ecommendation of the Joint Committee of Vaccination and Immunization(JCVI),the UK government is offering COVID-19 booster dose in Autumn 2023 to adults 65 years,residents in a care home for older adults,clinical risk group aged 6 months-64 years,frontline health and social care workers,household con

53、tact individuals of age 12-64 years for people with immunosuppression and caregiver or staffs of age 16-64 years for care homes for older adults.JCVI also advised the autumnprogram should aim to complete vaccination by early December 2023(Aug 2023)1The Ministry of Health of Italy announces a nationa

54、l vaccination campaign against COVID-19(2023/2024)to prevent mortality,hospitalization and severity of COVID-19 in elderly,highly frail people,pregnant women and health and social health workers.It is expected to be launched with the use of new updated monovalent XBB 1.5 formulation of mRNA and prot

55、ein vaccines(expected to be approved by EMA and AIFA for late summer/early autumn and doses are expected to be available by October)(Aug 2023)4The Standing Committee on Vaccination(STIKO)recommends further booster doses for people 6 months with increased risk,people 60 years of age,residents of care

56、 facilities,medical and nursing staff,preferably with a variant adapted mRNA vaccine(July 2023)2.Pregnant women,regardless of their age,should be vaccinated with Comirnaty and not Spikevax.Basic immunization and a booster is recommended to unvaccinated pregnant women in their second trimester(July 2

57、023)3France Ministry of Health and Prevention has prepared for autumn vaccination campaign for COVID-19 in 2023-2024.The campaign targets risk groups recommended by the French National Authority for Health(HAS)are people of 65 years,people with co-morbidities,pregnant women,immunocompromised people,

58、health workers and caregivers(July 2023)6.HAS is evaluating the place of Bimerax vaccine in the vaccination strategy and requires additional data from clinical trials and longer follow-up period before considering its use(June 2023)7Sources:1JCVI recommendation;2STIKO Germany;3STIKO Germany pregnant

59、 women;4Ministry of Health Italy;5Ministry of Health Spain;6France autumn booster campaign;7HAS evaluating Bimerax15Total COVID-19 vaccine doses administered at the regional levelAs of August 2023,EU4 and UK countries have administered 748 M dosesIQVIA Quarterly Pharmaceutical Market Outlook-August

60、20231513843,4916772,2074861301452,5252,5241069,00006,0001,0007,0004,0003,0002,0005,0008,000154192EU4+UKPharmergingJapan155143RoWUS7488,7092,951Total vaccinations(M of doses)Sources:IQVIA European Thought Leadership,31/08/2023.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe

61、 Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023.Note:Pharmerging countries include China,India,Brazil,Turkey,Russia,Indonesia,Bangladesh,Mexico,Saudi Arabia,Pakistan,Egypt,Algeria,Colombia;South Af

62、rica,Ukraine,Phillipines and VietnamSpainThailandUKBrazilGermanyFranceItalyChinaIndiaOther Pharmering(Sum)IranSouth KoreaOther RoW(Sum)16CountryVaccine doses per 100 peopleItaly244.9Germany230.6France227.8United Kingdom224.0Spain222.5China244.8Brazil225.9India155.7Other Pharmerging(Avg)158.0South Ko

63、rea250.2Thailand198.9Iran175.5Other RoW(Avg)110.7Vaccine doses per 100 peopleEU4 and the UK have administered more vaccines per hundred people than the United States and JapanIQVIA Quarterly Pharmaceutical Market Outlook-August 2023230.1187.1118.4200.0309.6300035050200100250150EU4&UKPharmergingRoWUn

64、ited StatesJapanSources:IQVIA European Thought Leadership,31/08/2023.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/coronavirus on 14/08/2023.Note:P

65、harmerging countries include China,India,Brazil,Turkey,Russia,Indonesia,Bangladesh,Mexico,Saudi Arabia,Pakistan,Egypt,Algeria,Colombia,South Africa,Ukraine,Phillipines and Vietnam17In European countries,the Pfizer vaccine is the most widely used vaccine,followed by the Moderna vaccineIQVIA Quarterly

66、 Pharmaceutical Market Outlook-August 2023Sources:IQVIA European Thought Leadership,31/08/2023.Vaccine rollout data:Max Roser,Hannah Ritchie,Esteban Ortiz-Ospina and Joe Hasell(2020)-Coronavirus Pandemic(COVID-19).Published online at OurWorldInData.org.Retrieved from:https:/ourworldindata.org/corona

67、virus on 14/08/2023Note:Vaccine rollout data by product is not reported for UK in OurWorldInData.org60%78%74%79%67%18%68%67%60%60%37%22%17%16%24%15%22%30%7%15%7%8%23%9%9%23%18%24%25%3%United States(22nd Mar)Japan(7th May)2%Germany(7th Apr)5%1%France(10th Jul)1%Italy(10th Aug)1%Argentina(12th Aug)2%S

68、pain(9th Jun)3%Canada(4th Dec)Peru(13th Aug)2%South Korea(26th May)672.6383.7186.5154.5144.6116.0112.995.290.187.5Vaccine rollout by product in reporting countries(M of doses)ValnevaSKYCovioneSanofi/GSKMedicagoNovavaxCanSinoSinopharm/BeijingSputnik VJohnson&JohnsonOxford/AstraZenecaModernaPfizer/Bio

69、NTech18As more drugs are developed,the majority of clinical trials for therapeutics are in early phasesCurrent COVID-19 pipeline is dominated by therapeutics;EU4&UK-based companies account for 14%of total drugs under developmentIQVIA Quarterly Pharmaceutical Market Outlook-August 202379353136319Phas

70、e I174Phase II103Phase III3Pre-reg4Registered91032914014495DNA based vaccineInactivated VirusLive attenuated virusProtein subunitRecombinant protein vaccineRNA based vaccineViral vector(Non-replicating)Viral vector(Replicating)Virus like particleOtherNumber of drugs by phaseSource:IQVIA Pipeline Int

71、elligence.Data exported on 11/08/2023;Notes:Data is excluded for vaccine candidates which are pre-clinical or terminated in development.Vector NR=Vector Non-replicating.Vector R=Vector Replicating.VLP=Virus Like Particle;*Corporation Nationality:Nationality of a corporation with a specific licensing

72、 relationship in a region or therapy franchiseVaccinesTherapeuticsNumber of Drugs by type of platform/class 166197TherapeuticsNon-BiologicBiologicUSRoWPharmergingEU4&UKJapan39%24%16%14%6%Drug records(%)by Corporation nationality*Drugs under development by corporation nationality,EU4&UK contribute 14

73、%of therapies in development,whereas the US lead with 39%The most prevalent COVID-19 therapy formulations in development are injectables and oral medications#of drugs by formulation18185211injectionOralinhalationintranasalInhalation/Injectiontopicaltransdermalsublingual29514719COVID-19 vaccination R

74、ecent news updatesIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Sources:IQVIA European Thought Leadership 31/08/2023.1EU vaccine update;2Moderna;3US FDA recommendation;4Japan monovalent vaccine;5Canada vaccine updateVaccine updates for new variantsFurther vaccine updates globallyVaccine m

75、anufacturers and regulatory authorities are focusing on updating booster shots for the new variants EMAs Emergency Task Force has recommended updating vaccines to target the dominant XBB strains of Omicron.The European Medicines Agency(EMA)and the European Centre for Disease Prevention and Control(E

76、CDC)also noted that monovalent vaccines may provide protection against present dominant and emerging strains(June 2023)1 EU Committee for Medicinal Products for Human Use(CHMP)recommends extension of marketing authorization for Spikevax Bivalent Original/Omicron BA.4-5 for active immunization to pre

77、vent COVID-19 in individuals 6 months of age(July 2023)2Globally,vaccine approvals continue for novel vaccines and approved vaccines are extended for wider age groups The Vaccine and Related Biological Products Advisory Committee(VRBPAC)of US FDA recommended COVID-19 vaccines to be updated with a mo

78、novalent formulation to provide protection against the Omicron variant XBB.1.5 for use by the fall of 2023(June 2023)3 Daiichi-Sankyos DAICHIRONA(monovalent-original strain)is the first Japan-made mRNA vaccine for COVID-19 that has been approved in Japan for manufacturing and marketing(August 2023)4

79、 Public Health Agency of Canada(PHAC)released updated guidelines on the use of COVID-19 vaccine.Updates include recommendations for the use of Moderna Spikevax Bivalent vaccine(Original/Omicron BA.1 and Original/Omicron BA.4/5)as a booster dose for individuals 6-17 years of age.Use of Novavax Nuvaxo

80、vid vaccine is also recommended as a primary series in individuals 12 years of age and as a booster dose for adults 18 years of age(June 2023)520Channel Preference Survey 2023 results21Source:IQVIA EMEA Thought LeadershipSix enablers for successful post-pandemic customer engagementEngaging with heal

81、th systems requires an orchestrated omnichannel approach to meet customer needsIQVIA Quarterly Pharmaceutical Market Outlook-August 2023IQVIATarget GroupChannel mixContentPeopleTechnologyChange AgilityCustomer focus22F2F and virtual remote contacts with HCPsCountries are now finding a new post-pande

82、mic equilibrium for traditional and digital interactionsDigital(Remote 1:1 calls)Traditional(F2F 1:1 visits)Culture and expectations HCP channel preferences COVID-19 response Access to physicians Limitations on in-person interactions Promotional necessity Schedule around clinic time02,0004,0006,0008

83、,00010,00012,00014,000 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023Number of Contacts(000s)FranceGermanyItalySpainUK02004006008001,0001,200 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 20

84、22 Q3 2022 Q4 2022 Q1 2023 Q2 2023Number of Contacts(000s)FranceGermanyItalySpainUKSource:IQVIA EMEA Thought Leadership;IQVIA ChannelDynamics Data(EU4&UK,all specialties,all therapy areas)IQVIA Quarterly Pharmaceutical Market Outlook-August 202323Spain and the UK show the highest affinity for remote

85、 engagementLife sciences companies need to make the most of interactive time with HCPs,which remains below pre-pandemic levels1:1 Interactive Contact Time by ChannelVirtual 1:1 callF2F DetailTelephone5%4%97%3%80%H1 201963%16%H1 202011%25%63%63%H1 20216%10%85%H1 20226%69%89%H1 2023100%58%H1 2023H1 20

86、1912%H1 202085%3%97%94%4%6%6%3%87%H1 20214%5%91%H1 20223%100%62%82%72%67%73%3%1%83%12%100%98%H1 20195%H1 20206%71%91%H1 20215%H1 202394%H1 20224%95%54%71%7%20%5%63%93%18%H1 201922%88%15%H1 20208%63%100%H1 202111%82%H1 20225%86%H1 202375%84%88%88%H1 202013%6%45%93%H1 201921%65%30%25%H1 202127%16%57%H

87、1 202261%18%12%70%H1 2023100%63%75%97%114%85%16%2%H1 201916%67%H1 202090%26%12%62%H1 202113%108%9%77%H1 20228%7%H1 2023100%122%GermanyFranceItalySpainUKUSSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 2023IQVIA Quarterly Pharmaceutical Market Outlook-August 202324The 2023 IQVIA Chann

88、elDynamics Channel Preference Survey covered over 23,000 HCPs across 38 countriesRespondents by SpecialtySplit of respondents by care setting10%24%14%56%17%90%76%86%44%83%APACEU4+UKLATAMNordicsUSPrimarySecondaryTotal23,2531,1021,5973,4191,7519691,845+33 other countries12,57019%8%5%5%4%4%4%4%4%4%4%3%

89、3%3%3%3%2%2%2%12%GPsPharmacistsCardiologistsGynaecologistsInternal MedicinePsychiatristsOncologistsPaediatriciansRheumatologistsGastroenterologistsOpthamologistsDermatologistsPulmonologistsNeurologistsUrologistsDiabetologistsHaematologistsOrthopaediatriciansNephrologistsOthers“Please enter-as a perc

90、entage the mix of interactions you would generally prefer over the course of a year.For example,if you would prefer about half of your interactions to be face-to-face,1:1 in-person visits,please indicate 50%”Source:IQVIA EMEA Thought Leadership;Channel Preference Survey 2023IQVIA Quarterly Pharmaceu

91、tical Market Outlook-August 202325Aggregated EU4&UK and US channel preference splitsF2F visits,in-person conferences and emails uphold the top three positions as the most preferred channels over timeF2F 1:1 visit41%In-person conferences16%Email10%Remote,live-streamed conferences9%On-demand presentat

92、ions6%Post/mail5%Remote 1:1 video call4%Instant message/text4%Telephone3%Podcasts2%Other0%51%44%11%18%9%9%0%10%20%30%40%50%60%70%80%90%100%20212022Online resourcesPodcastsTelephoneInstantmessage/text1:1 video callPost/mailOn-demandpresentationsRemoteconferencesEmailIn-personconferenceF2F 1:1 visit20

93、23Source:IQVIA EMEA Thought Leadership;Channel Preference Survey 2023IQVIA Quarterly Pharmaceutical Market Outlook-August 2023262023 preferred channel mix across major marketsGlobally,F2F is the most preferred channel but there is significant regional and country-level variation39%42%42%28%40%42%41%

94、15%17%20%24%19%17%11%7%12%9%11%10%7%14%0%10%20%30%40%50%60%70%80%90%100%APACEU4+UKLATAMNordicsRest of EuropeRest of WorldUSPodcastsTelephoneInstant message/textRemote 1:1 videocallOn-demandpresentationsRemoteconferencesPost/MailEmailIn-personconferencesFace-to-face 1:1visits0%10%20%30%40%50%60%70%80

95、%90%100%GreeceSpainItalyPortugalTurkeyBelgiumFranceFinlandUnited StatesIrelandPolandNorwayGermanySwitzerlandUnited KingdomSwedenDenmark Face-to-face 1:1 visits In-person conferences EmailRemoteRegional AnalysisCountry AnalysisSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 2023IQVIA Q

96、uarterly Pharmaceutical Market Outlook-August 202327HCP Promotional Channel Preference over time(July 2019 July 2023)Significant country level variation in channel preference continues into 202310%12%15%42%52%17%21%23%22%23%22%26%34%25%64%44%36%1%201920209%202120222023Individual InteractionsMeetings

97、/Events/SeminarsOnline ResourcesOther4%37%48%16%14%18%28%26%12%29%27%35%26%67%54%48%1%20191%20204%2021202220238%47%53%18%19%17%19%17%13%23%24%33%29%62%52%54%201920207%20216%202220235%5%47%48%13%18%20%21%11%24%21%32%31%71%58%56%1%20191%202014%4%2021202220235%11%38%49%19%24%27%20%22%21%30%27%41%29%54%

98、39%35%1%20191%20206%20216%2022202311%35%46%20%25%23%17%17%10%17%18%47%36%63%52%49%201920207%20216%20222023GermanyFranceItalySpainUKUSSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 2023;Individual interactions refers to face to face rep visits,one to one telephone and video call;meeti

99、ngs/events cover live and remote conferences;online resources refer to email,online information resources,self guided presentation and podcasts(2023);other cover instant messaging and postal mailingIQVIA Quarterly Pharmaceutical Market Outlook-August 202328HCP Preference for Individual Interactions(

100、2019-2023)HCP preference for individual interactions has remained higher than pre-pandemic in France,Italy,Spain and the US34%35%33%32%41%47%64%66%62%70%54%63%44%54%50%48%39%46%36%48%54%56%35%49%2019 Pre-pandemic2021 Without restrictions2022 Without restrictions2023 channel preferenceIndividual Inte

101、ractionsFace-to-face,one-to-one visits1:1 Telephone call(audio only)1:1 video call(e.g.,via Zoom,Teams etc.)Instant message/text(e.g.,via WhatsApp)GermanyFranceItalySpainUKUSSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 2023IQVIA Quarterly Pharmaceutical Market Outlook-August 202329

102、42%31%47%49%24%41%30%39%25%25%43%35%0%10%20%30%40%50%60%70%80%90%100%FranceGermanyItalySpainUKUSPodcastsInstant messagingTelephoneLive video call with individual repOn-demand presentationsPostVirtual conferencesRemoteEmailIn-person conferencesF2F 1:1 visitsBuilding the case for omnichannel interacti

103、ons across the EU4&UKRemote channels contribute to 25-43%of overall preference,showing how a shift from F2F are needed in certain marketsIQVIA Quarterly Pharmaceutical Market Outlook-August 2023GermanyItalySpainUKFranceUSSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 202330Life scien

104、ces companies need to engage with an older demographic today but also need to focus on a younger,more digitally astute customer base in futureDigital natives and immigrants show significant channel preference alignment,with natives preferring marginally less F2FIQVIA Quarterly Pharmaceutical Market

105、Outlook-August 202345%38%17%19%11%12%5%7%0%10%20%30%40%50%60%70%80%90%100%Digital Immigrant(Born pre-1980,n=4,804)Digital Native(Born post-1980,n=997)2023 channel preference analysis split by age segment across the EU4&UK Face-to-face 1:1 visits In-person conferences Email Post/Mail Remote conferenc

106、es On-demand presentations Remote 1:1 video call Instant message/text Telephone Podcasts14%32%42%45%56%0%10%20%30%40%50%60%UKTurkeyIrelandFinlandNetherlandsCroatiaRomaniaPortugalSwedenGreeceDenmarkSpainAustriaCzech RepublicSwitzerlandIcelandLuxembourgBelgiumFranceBulgariaGermanyHungaryEstoniaLatviaI

107、srealItaly%of medical doctors 55 years by country Source:IQVIA EMEA Thought Leadership;%Medical doctors aged 55 and above by country(World Health Organisation);Channel Preference Survey 202331EU4&UK and US channel preferences,split by genderThe 2023 survey shows limited differences in channel prefer

108、ences between men and womenIQVIA Quarterly Pharmaceutical Market Outlook-August 2023(n=3,696)(n=6,947)UK0%20%40%60%80%100%FemaleMaleFemaleMaleFemaleMaleFemaleMaleFemaleMaleFemaleMaleSpainItalyGermanyFranceAggregated channel preferenceGender splits by country43%38%0%10%20%30%40%50%60%70%80%90%100%Mal

109、eFemale Podcasts Text/Instant message Telephone Remote 1:1 video call Post/Mail On-demandpresentations Remote conferences Email In-person conferenceUSIndividual InteractionsMeetings/Events/SeminarsOnline ResourcesOtherSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 202332Primary vs.se

110、condary HCP channel preferences in US,EU4&UKSecondary care HCPs prefer more group events than HCPs from primary careIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Individual interactionsMeetings/events/seminarsOnline resourcesOtherGermanyItalySpainUKFrance0%10%20%30%40%50%60%70%80%90%100%F

111、ranceGermanyItalySpainUnitedKingdomUnitedStates1 21 21 21 21 21 2USSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 202333HCP specialty level analysis across EU4&UKGPs show an affinity towards individual interactions in the EU4 but in the UK many prefer online resourcesIQVIA Quarterly

112、Pharmaceutical Market Outlook-August 2023UK0%10%20%30%40%50%60%70%80%90%100%GPsOncologistsCardiologistsGPsOncologistsCardiologistsGPsCardiologistsOncologistsGPsCardiologistsOncologistsCardiologistsOncologistsGPsSpainItalyGermanyFranceSource:IQVIA EMEA Thought Leadership;Channel Preference Survey 202

113、3Individual interactionsMeetings/events/seminarsOnline resourcesOther34Four key components from the Channel Preference Survey to create HCP personaeWhat are the strongest factors influencing the commercial approach for life sciences companies?IQVIA Quarterly Pharmaceutical Market Outlook-August 2023

114、Country Culture,historical expectations and accessSpecialty Different priorities,workloads and patient groupsAge Digital affinity,social media and generational normsGender Limited differences in channel preferenceBuilding HCP personaeHCP archetypes need to reflect channel preferences and desire to i

115、nteractE.g.,traditional in-person,digital-only,hybrid etc.(weekly,monthly)Incorporate multiple data sources E.g.,age,gender,specialty,engagement history,prescription volumes,social media presence and digital affinitySource:IQVIA EMEA Thought Leadership35New Active Substance,plus Innovative Launch An

116、alysis36On average,post-pandemic launch trajectories still underperform,and the most recent cohort perform worstIQVIA Quarterly Pharmaceutical Market Outlook-August 20231234567891011124051623-27%Median cumulative sales(Mn USD)Performance of innovative launches pre-COVID versus post-COVIDMedian cumul

117、ative sales for innovative launches across the Top 8 marketsMonths since launchPandemic/Post-Pandemic AverageH1 2022Pre-pandemic20212020H2 2022Source:IQVIA EMEA Thought Leadership;IQVIA MIDAS Monthly June 2023;Notes:Rx only;USD in CER;Pre-pandemic launches:H2 2016 to 2019;Includes NAS launches as we

118、ll as other launches considered to be significantly innovative(e.g.non-NAS launches in a new therapy area,orphan disease or new combinations including an innovative branded medicine);Excludes Hep C products,COVID-19 Vaccines and Treatments;Countries included are US,China,Japan,UK,Germany,Italy,Franc

119、e,SpainTop 8 COVID-19 vaccines and treatments Hep C products Excludes37You can explore more Thought Leadership on Launch on the IQVIA websiteIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Post Pandemic Launch EnvironmentLaunch Excellence VIIIOvercoming Pharmas Launch Performance ProblemSuc

120、cess Multiplied:Launch Excellence for Multi-Indication AssetsLaunch Excellence VIICommercial modelEditing the DNA of Pharmas Go to Market modelHCP Channel Preference in an increasingly complex landscape Riding out the storm:The future of post-Pandemic customer engagementTranscending the traditional

121、focus of oncology commercialisationReal World Evidence/Medical AffairsExcellent launches are winning the evidence battleMaking Real World Evidence meaningful and actionableTheir Finest Hour:Medical Affairs in a Disrupted World IQVIAMedical affairs next frontier:Unlocking Omnichannel EngagementIn the

122、 thick of it:Medical Affairs,strategic partner to other functionsTherapy areaA new dawn:At the cusp of the CNS decadePaving the path in haematological cancersIn the Eye of the Storm:PD-(L)1 inhibitorsCell,Gene and RNA:A decade of progressCompany typeLarge pharma launch issues:No more surprises:Under

123、standing predictors of Launch success(with AZ)Launch Excellence:Escaping the complexity TrapEBP launch issues:Emerging Biopharma challenges of European commercialisationOPEXRe-defining OPEX Modelling for a Competitive FutureGrowth through Commercial38Sign up for our September 14thLaunch Excellence w

124、ebinarhttps:/ Demand and Supply40COVID-19 ReportedNumbers*Total Cases25,940,84038,437,75613,980,34040,086,99924,680,562Total Deaths191,211174,979121,852171,684228,802Increase in Volume growth in Germany&UK across all segments YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutic

125、al Market Outlook-August 2023CH Market Units GrowthYTD-2023 vs.20221-9.8%4.1%-24.6%-4.0%0.3%Latest Month4-9.2%-2.9%-23.3%-1.6%3.3%Rx Retail Units GrowthYTD-2023 vs.20222-2.0%4.7%3.0%0.3%4.6%Latest Month4-2.4%8.0%0.2%1.5%9.7%Rx Hospital Units GrowthYTD-2023 vs.202232.2%3.2%4.4%7.3%5.5%Latest Month40.

126、6%3.6%-2.8%10.9%10.4%Note:Retail pharmacy sales/Rx data has been used across countries.Any cross-country analysis needs to account for differences in healthcare systems.1IQVIA CH Customized Insights Italy,Germany,Spain,France(Monthly sell-out data),UK(Monthly sell-in data);Only OTC segment coverage

127、for UK2IQVIA MIDAS data Retail panel Italy,Germany,Spain,France(Monthly sell-out data),UK(Monthly sell-in data)3Monthly IQVIA MIDAS data Hospital panel Italy,Germany,Spain,France,UK4Latest month August 2023*Source:COVID-19 Epi data in the WHO European Region(WHO),data extracted on 29thAugust 202341-

128、40%-20%0%20%40%60%80%Sep-21Dec-21Mar-22Jun-22Sep-22Dec-22Mar-23Jun-23%Growth UnitsMonths%Growth Units Current Year vs.Same Month Previous YearEU4&UKThe consumer health market is declining,except in the UKUK and France showed highest volume growth in retail and hospital market respectively in June 20

129、23IQVIA Quarterly Pharmaceutical Market Outlook-August 2023Retail Rx marketHospital marketConsumer Health market-40%-20%0%20%40%60%80%Sep-21Dec-21Mar-22Jun-22Sep-22Dec-22Mar-23Jun-23%Growth UnitsMonths%Growth Units Current Year vs.Same Month Previous YearEU4&UKItalyGermanySpainFranceUK-40%-20%0%20%4

130、0%60%80%Sep-21Dec-21Mar-22Jun-22Sep-22Dec-22Mar-23Jun-23%Growth UnitsMonths%Growth Units Current Year vs.Same Month Previous YearEU4&UKSource:IQVIA CH Customized Insights,IQVIA MIDAS data(Retail panel)Italy,Germany,Spain,France(Monthly sell-out data),UK(Monthly sell-in data);Monthly IQVIA MIDAS data

131、 Hospital panel;August 202342The Italian retail prescription volume sales declined by 2%YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-60%-40%-20%0%20%40%60%80%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-2

132、2Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.Same Month Previous YearTotal market and Top 5*YTD 2023Rx MarketAntiparasitic products,insecticides and repellentsAntiinfectives for systemic useRespiratory systemSensory organsSystemic hormonal preparations,excluding sex

133、 hormones and insulins*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly sell-out data August 2023|Retail pharmacy panel captures sales of Rx products only%Growth UnitsMonthsTop*2 ATC3 classes within Top*5 ATC1 classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Gro

134、wth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022Rx Market-0.9%-2.4%-2.0%Antiparasitic products,insecticides andrepellents31.5%17.6%26.0%Anti-Malarials75.0%20.0%32.3%Anthelmintics25.0%17.5%23.6%Antiinfectives for systemic use26.0%-0.7%18.8%Cephalosporins&Combs56.7%7.4%36.0%Broad Spectr.Peni

135、cillins39.3%2.8%26.5%Respiratory system35.6%2.3%8.7%Corticoids107.5%-9.7%35.8%Anticholinergics In Combination With B2-Agonists50.8%26.8%29.9%Sensory organs11.1%2.3%6.4%Ophth A-Inflam+A-Infect24.2%12.4%15.8%Miotics+Antiglauc.Preps.2.3%-2.1%0.3%Systemic hormonal preparations,excluding sex hormones and

136、 insulins17.9%-2.7%3.7%Plain Corticosteroids27.4%-6.5%5.7%Thyroid Preparations6.2%1.5%1.5%43-100%0%100%200%300%400%500%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units in Current Year vs.Same Month Previ

137、ous YearTotal hospital market and Top 5*YTD 2023Hospital totalAntiparasitic products,insecticides and repellentsRespiratory systemAntineoplastic and immunomodulating agentsSensory organsMusculo-skeletal systemThe hospital market in Italy grew by 2.2%in YTD 2023 compared to 2022IQVIA Quarterly Pharma

138、ceutical Market Outlook-August 2023*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly data August 2023|Hospital panel%Growth UnitsMonthsTop*6 ATC Classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023vs.2022Hospital

139、 Market5.5%0.6%2.2%Antiparasitic products,insecticides andrepellents300.0%140.0%133.3%Respiratory system31.9%3.3%15.4%Antineoplastic and immunomodulatingagents10.2%5.9%6.8%Sensory organs25.6%3.1%6.3%Musculo-skeletal system7.6%1.5%5.0%Genito-urinary system and sex hormones6.3%9.5%4.0%44The Consumer h

140、ealth market in Italy declined by 9.8%in YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-120%-70%-20%30%80%130%180%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun

141、-23%Growth Units Current Year vs.Same Month Previous YearCH market and CH categoriesCH MarketNTROTCPACPEC*Top in terms of YTD 2023 GrowthSource:IQVIA CH Customized Insights monthly sell-out data August 2023%Growth UnitsMonthsCH Categories and top*2 classes within each category by Units Growth YTD 20

142、23 vs.2022Units Growth Jan 2023 vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022CH Market-15.0%-9.2%-9.8%Nutrition(NTR)-3.7%-5.1%-5.4%Gluten-Free&Low Prot.Prds-2.2%-0.6%-2.7%Food For Adults-4.7%-9.2%-7.1%Over-the-Counter Drugs(OTC)7.83%-5.0%3.2%Cough,Cold and Other Respirat

143、ory Products23.5%-14.3%14.8%Digest&Oth Intest Prod14.1%2.0%9.0%Patient Care(PAC)-60.2%-32.2%-44.8%Incontinence Care Prds6.7%2.5%3.2%Prds For Bladder Problems-1.3%-0.6%-0.8%Personal Care(PEC)-1.9%-5.3%-3.7%Beauty Products For Women12.8%2.8%4.7%Unisex Beauty Products11.2%0.8%-0.2%45The German retail m

144、arket grew by 4.7%YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-40%-20%0%20%40%60%80%100%120%140%160%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth U

145、nits Current Year vs.Same Month Previous YearTotal market and Top 5*YTD 2023Rx MarketAntiparasitic products,insecticides and repellentsAntiinfectives for systemic useSensory organsRespiratory systemAntineoplastic and immunomodulating agents*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly s

146、ell-out data August 2023|Retail pharmacy panel captures sales of Rx products only%Growth UnitsMonthsTop*2 ATC3 classes within Top*5 ATC1 classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022Rx Market10.0%8.0%4.7%An

147、tiparasitic products,insecticides andrepellents28.7%22.5%25.7%Ectoparas.Incl Scabicide26.9%15.2%24.6%Anthelmintics10.0%17.9%14.4%Antiinfectives for systemic use-2.1%18.9%17.4%Bacterial Vaccines38.9%25.0%24.5%Polyval Immuno-Globl I.V0.0%18.2%7.2%Sensory organs19.7%27.5%17.0%Miotics+Antiglauc.Preps.4.

148、8%9.5%3.7%Ocular Antineovasc.Prods-9.2%8.9%-0.6%Respiratory system28.0%2.5%11.0%All Oth A-Asthma&Copd14.3%42.9%22.7%Cystic Fibrosis Products20.0%14.3%13.5%Antineoplastic and immunomodulatingagents10.5%10.3%4.9%Interleukin Inhibitors21.9%23.5%19.0%Protein Kinase Inhibitor Antineoplastics12.1%14.3%11.

149、5%46-60%-40%-20%0%20%40%60%80%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units in Current Year vs.Same Month Previous YearTotal hospital market and Top 5*YTD 2023Hospital totalAntiparasitic products,inse

150、cticides and repellentsRespiratory systemSensory organsAntiinfectives for systemic useNervous systemThe German hospital market grew by 3.2%in YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS mont

151、hly data August 2023|Hospital panel%Growth UnitsMonthsTop*6 ATC Classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023vs.2022Hospital Market6.9%3.6%3.2%Antiparasitic products,insecticides andrepellents39.3%44.2%29.7%Respira

152、tory system26.1%10.3%19.9%Sensory organs10.9%9.5%6.3%Antiinfectives for systemic use12.2%1.4%5.6%Nervous system8.4%2.0%5.4%Cardiovascular system11.3%1.5%4.9%47-40%-20%0%20%40%60%80%100%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23A

153、pr-23May-23Jun-23%Growth Units Current Year vs.Same Month Previous YearTotal market and Top 5*YTD 2023CH MarketNTROTCPACPECThe consumer health market in Germany grew by 4.1%YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023*Top in terms of YTD 202

154、3 GrowthSource:IQVIA CH Customized Insights monthly sell-out data August 2023%Growth UnitsMonthsCH Categories and top*2 classes within each category by Units Growth YTD 2023 vs.2022Units Growth Jan 2023 vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022CH Market7.2%-2.9%4.1%N

155、utrition(NTR)3.2%-0.5%2.0%Enteral Nutrition Products28.6%9.3%13.3%Baby Foods-17.7%-27.6%-19.9%Over-the-Counter Drugs(OTC)12.36%-2.4%7.9%Cough,Cold And Other Respiratory Products30.2%-9.5%16.6%Vitamins,Minerals And Nutritional Supplements,Tonics And Other Stimulants6.5%6.3%7.4%Patient Care(PAC)-25.5%

156、-15.8%-22.8%Incontinence Care Prds7.8%10.2%9.1%Advanced Dressings7.5%3.5%1.9%Personal Care(PEC)5.4%10.8%3.6%Unisex Beauty Products8.9%20.5%5.4%Beauty Products For Women2.8%5.1%2.5%48The Spanish retail market grew by 3%YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Marke

157、t Outlook-August 2023-20%0%20%40%60%80%100%120%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.Same Month Previous YearTotal market and Top 5*YTD 2023Rx MarketAntiparasitic products,inse

158、cticides and repellentsAntiinfectives for systemic useRespiratory systemGenito-urinary system and sex hormonesSensory organs*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly sell-out data August 2023|Retail pharmacy panel captures sales of Rx products only%Growth UnitsMonthsTop*2 ATC3 class

159、es within Top*5 ATC1 classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022Rx Market7.3%0.2%3.0%Antiparasitic products,insecticides andrepellents63.0%44.6%36.6%Anti-Malarials100.0%34.8%51.5%Anthelmintics58.4%37.6%38

160、.4%Antiinfectives for systemic use34.4%-1.2%19.0%Broad Spectr.Penicillins44.2%4.1%26.7%Cephalosporins&Combs40.2%1.8%22.1%Respiratory system25.2%-11.1%7.7%Anticholinergics In Combination With B2-Agonists23.4%19.0%19.7%Antihistamines Systemic29.9%-11.6%9.9%Genito-urinary system and sex hormones5.4%8.1

161、%4.6%Urinary Incontinence Prd7.5%7.8%6.9%Bph Products3.8%4.0%4.7%Sensory organs14.7%-0.6%4.6%Anti-Infectives-Eye34.1%-0.9%11.4%Ocul.A-Aller.Decon.A-Sep3.1%-14.5%2.5%49-100%0%100%200%300%400%500%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-

162、23Mar-23Apr-23May-23Jun-23%Growth Units in Current Year vs.Same Month Previous YearTotal hospital market and Top 5*YTD 2023Hospital MarketAntiparasitic products,insecticides and repellentsRespiratory systemAntineoplastic and immunomodulating agentsSensory organsGenito-urinary system and sex hormones

163、The Spanish hospital market grew by 4.4%YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly data August 2023|Hospital panel%Growth UnitsMonthsTop*6 ATC Classes by Units Growth YTD 2023 vs.YT

164、D 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023vs.2022Hospital Market9.0%-2.8%4.4%Antiparasitic products,insecticides andrepellents50.0%12.5%70.1%Respiratory system42.9%6.5%26.4%Antineoplastic and immunomodulatingagents14.1%6.1%10.4%Sensory organs26.4%7.

165、2%8.3%Genito-urinary system and sex hormones17.8%0.9%8.2%Antiinfectives for systemic use13.2%-0.6%6.2%50-100%-50%0%50%100%150%200%250%300%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.

166、Same Month Previous YearCH market and CH categoriesCH MarketNTROTCPACPECThe Spanish consumer health market declined by 24.6%in YTD 2023 compared to the same period in 2022IQVIA Quarterly Pharmaceutical Market Outlook-August 2023*Top in terms of YTD 2023 GrowthSource:IQVIA CH Customized Insights mont

167、hly sell-out data August 2023%Growth UnitsMonthsCH Categories and top*2 classes within each category by Units Growth YTD 2023 vs.2022Units Growth Jan 2023 vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022CH Market-40.0%-23.3%-24.6%Nutrition(NTR)5.5%-4.3%0.4%Enteral Nutrition

168、 Products9.1%-0.4%5.4%Baby Foods5.8%-1.5%3.0%Over-the-Counter Drugs(OTC)11.19%-9.2%3.3%Cough,Cold And Other Respiratory Products36.1%-28.0%13.0%Digest&Oth Intest Prod11.0%-1.1%4.1%Patient Care(PAC)-73.8%-52.6%-59.1%Stomacare Products6.7%9.1%7.2%Orthopaed/Antirheum Aid10.7%9.5%5.2%Personal Care(PEC)7

169、.3%-0.4%2.6%Unisex Beauty Products31.8%0.2%12.4%Beauty Products For Women11.5%0.5%5.9%51The French retail market grew by 0.3%YTD 2023 compared to the same period year agoIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-20%-10%0%10%20%30%40%50%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22

170、May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.Same Month Previous YearTotal market and Top 5*YTD 2023Rx MarketAntineoplastic and immunomodulating agentsSensory organsGenito-urinary system and sex hormonesRespiratory systemAlimentary

171、 tract and metabolism*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly sell-out data August 2023|Retail pharmacy panel captures sales of Rx products only%Growth UnitsMonthsTop*2 ATC3 classes within Top*5 ATC1 classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Grow

172、th Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022Rx Market4.1%1.5%0.3%Antineoplastic and immunomodulatingagents7.8%5.7%5.0%Anti-Tnf Products14.4%9.4%9.8%Protein Kinase Inhibitor Antineoplastics9.0%9.7%7.2%Sensory organs9.3%7.0%4.7%Ocular Antineovasc.Prods12.0%7.0%7.6%Miotics+Antiglauc.Preps.

173、3.9%2.2%1.6%Genito-urinary system and sex hormones3.3%2.0%0.9%Erectile Dysfunction Prd10.8%6.0%5.7%Gonadotrophins7.5%5.4%4.7%Respiratory system6.5%6.1%0.8%Anticholinergics In Combination With B2-Agonists14.0%12.2%10.6%All Oth A-Asthma&Copd9.1%6.4%5.9%Alimentary tract and metabolism2.9%2.1%0.8%Glp-1

174、Agonist A-Diabs25.0%21.4%21.2%Other Metabolic Products3.6%5.7%2.9%52-40%-30%-20%-10%0%10%20%30%40%50%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units in Current Year vs.Same Month Previous YearTotal hosp

175、ital market and Top 5*YTD 2023Hospital MarketRespiratory systemAntineoplastic and immunomodulating agentsGenito-urinary system and sex hormonesAlimentary tract and metabolismSystemic hormonal preparations,excluding sex hormones and insulinsThe Hospital market in France grew 7.3%YTD compared to the s

176、ame period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023%Growth Units*Top in terms of YTD 2023 GrowthSource:IQVIA MIDAS monthly data August 2023|Hospital panelMonthsTop*6 ATC Classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 v

177、s.2022Units Growth YTD 2023vs.2022Hospital Market6.9%10.9%7.3%Respiratory system12.8%18.2%12.9%Antineoplastic and immunomodulatingagents7.2%13.2%10.5%Genito-urinary system and sex hormones10.3%13.0%9.1%Alimentary tract and metabolism6.9%14.1%8.7%Systemic hormonal preparations,excluding sex hormones

178、and insulins9.1%14.9%8.7%Cardiovascular system8.5%13.3%8.3%53The French consumer health market declined by 4%YTD 2023 compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-60%-40%-20%0%20%40%60%80%100%120%140%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22Ma

179、y-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.Same Month Previous YearCH market and CH categoriesCH MarketNTROTCPACPEC*Top in terms of YTD 2023 GrowthSource:IQVIA CH Customized Insights monthly sell-out data August 2023%Growth UnitsMo

180、nthsCH Categories and top*2 classes within each category by Units Growth YTD 2023 vs.2022Units Growth Jan 2023 vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022CH Market-4.9%-1.6%-4.0%Nutrition(NTR)8.2%4.6%4.5%Enteral Nutrition Products11.7%7.5%6.8%Baby Foods-0.5%-2.6%-1.8%O

181、ver-the-Counter Drugs(OTC)-0.04%-3.0%-2.7%Eye Care12.0%15.3%7.9%Cough,Cold And Other Respiratory Products15.1%-12.4%3.3%Patient Care(PAC)-39.4%-13.9%-24.0%Advanced Dressings14.9%7.6%6.1%Surgical Absorbents5.5%4.1%0.2%Personal Care(PEC)0.8%9.8%2.1%Unisex Beauty Products9.4%25.2%10.3%Beauty Products F

182、or Women6.2%6.9%4.6%54The UK retail prescription market grew by 4.6%in YTD 2023 compared to same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-40%-20%0%20%40%60%80%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23

183、Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.Same Month Previous YearTotal retail Rx market and Top 5*ATC classesRx MarketAntiinfectives for systemic useGenito-urinary system and sex hormonesSensory organsCardiovascular systemAlimentary tract and metabolism*Top in terms of YTD 2023 GrowthSo

184、urce:IQVIA MIDAS monthly sell-in data August 2023|Retail pharmacy panel captures sales of Rx products onlyTop*2 ATC3 classes within Top*5 ATC1 classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022Rx Market6.3%9.7%4

185、.6%Antiinfectives for systemic use36.8%8.9%18.1%Viral Vaccines49.2%32.7%33.7%Broad Spectr.Penicillins62.5%7.1%30.0%Genito-urinary system and sex hormones17.4%18.9%14.2%Urinary Anti-Infectives5.1%21.8%13.0%Erectile Dysfunction Prd5.0%13.3%5.8%Sensory organs6.7%12.3%6.4%Ocul.A-Aller.Decon.A-Sep3.1%22.

186、6%8.5%Miotics+Antiglauc.Preps.4.4%8.4%3.3%Cardiovascular system5.3%11.4%5.0%Cholest&Trigly.Regulator7.4%15.5%8.0%Calcium Antagonist Plain7.6%13.3%7.2%Alimentary tract and metabolism5.4%10.0%4.5%Sglt2 Inhibitor Antidiabetics47.6%49.4%44.3%Glp-1 Agonist A-Diabs28.8%33.1%23.5%Growth RxMonths55-50%0%50%

187、100%150%200%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units in Current Year vs.Same Month Previous YearTotal hospital market and Top 5*YTD 2023Hospital MarketAntineoplastic and immunomodulating agentsAn

188、tiparasitic products,insecticides and repellentsRespiratory systemNervous systemSystemic hormonal preparations,excluding sex hormones and insulinsThe UK hospital market grew by 5.5%YTD 2023 compared to the same period in 2022IQVIA Quarterly Pharmaceutical Market Outlook-August 2023*Top in terms of Y

189、TD 2023 GrowthSource:IQVIA MIDAS monthly data August 2023|Hospital panel%Growth UnitsTop*6 ATC Classes by Units Growth YTD 2023 vs.YTD 2022Units Growth Jan 2023vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023vs.2022Hospital Market12.2%10.4%5.5%Antineoplastic and immunomodulatingage

190、nts14.2%15.6%9.9%Antiparasitic products,insecticides and repellents21.4%6.7%8.8%Respiratory system22.5%7.9%7.9%Nervous system12.8%9.8%6.7%Systemic hormonal preparations,excluding sex hormones and insulins15.1%8.5%6.4%Alimentary tract and metabolism8.8%15.9%6.3%Months56The UK consumer health market g

191、rew by 0.3%YTD compared to the same period last yearIQVIA Quarterly Pharmaceutical Market Outlook-August 2023-10%-5%0%5%10%15%20%Sep-21Oct-21Nov-21Dec-21Jan-22Feb-22Mar-22Apr-22May-22Jun-22Jul-22Aug-22Sep-22Oct-22Nov-22Dec-22Jan-23Feb-23Mar-23Apr-23May-23Jun-23%Growth Units Current Year vs.Same Mont

192、h Previous YearCH market and CH categoriesRx marketOTC*Top in terms of YTD 2023 GrowthNote:IQVIA CH Customized Insights Data has coverage of only OTC segment(CHC 1-19,97 classes)Source:IQVIA CH Customized Insights monthly sell-in data August 2023CH Categories and top*2 classes within each category b

193、y Units Growth YTD 2023 vs.2022Units Growth Jan 2023 vs.2022Units Growth Latest month 2023 vs.2022Units Growth YTD 2023 vs.2022CH Market11.6%3.3%0.3%Over-the-Counter Drugs(OTC)11.6%3.3%0.3%Cough,Cold And Other Respiratory Products38.9%6.2%8.5%Vitamins,Minerals And Nutritional Supplements,Tonics And

194、Other Stimulants2.4%7.4%0.9%Skin Treatment1.4%11.5%0.0%Digest&Oth Intest Prod5.6%3.3%-0.7%Pain Relief14.3%-4.0%-4.6%Growth UnitsMonths57Engagement with Health Care Professionals58Share of F2F&Remote interaction in promotional volume20193%7%97%92%88%202110%12%202090%8%202293%MAT 2023-27%+5%-12%-5%Maj

195、or markets:Full year 2019 vs.2020 vs.2021 vs.2022 and MAT July 2023ChannelDynamics:Channel volume trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 2023Source:IQVIA ChannelDynamics,F2F includes F2F detailing and F2F meetings,Remote includes phone detailing,e-detailing(live),e-meetings(live)

196、201986%25%3%97%75%202082%18%202114%89%202211%MAT 2023-31%-6%-4%-3%MAT 202320194%202211%202198%2%89%6%94%202095%5%96%-39%+12%-3%-1%93%7%71%41%201959%202029%202184%16%202286%14%MAT 2023-29%+9%0%-1%201991%20229%58%32%42%202068%202155%45%63%37%MAT 2023-39%-1%+12%+4%SpainUKItalyGermanyFrance59Share of pr

197、ojected promotional volumeItaly:Full year 2019 vs.2020 vs.2021 vs.2022 and year-to-date trends over 5-yearsChannelDynamics:Channel volume and performance trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202338%37%39%40%40%43%43%42%42%42%20%20%19%18%18%YTD 2022YTD 2019YTD 2021YTD 2020YTD 20

198、23PromotersPassivesDetractorsNPS Categoryshare55%56%56%57%56%45%44%44%43%44%YTD 2019YTD 2022YTD 2020YTD 2021YTD 2023Converted CallsNon Converted CallsConvertedCalls0%8%95%0%0%2%0%1%3%0%1%84%1%0%2%1%1%0%9%2020202184%0%0%1%2%2%8%4%20223%6%0%78%0%20191%0%0%50.8 M33.8 M37.2 M36.2 M0%-33%+10%-3%3%95%0%1%

199、1%0%0%1%85%1%0%YTD Jul20192%1%0%0%75%0%7%19.4 M2%YTD Jul202122.3 M0%YTD Jul20220%3%2%2%0%0%2%4%0%0%1%23.2 M84%YTD Jul202385%YTD Jul20201%10%1%2%0%1%10%8%4%8%31.9 M22.2 M-39%+20%-4%0%F2F-Detailing with RepF2F-Meetings/EventsRemote-Meetings/Events(Live,Streaming)Remote-Detailing with Rep(Telephone,voi

200、ce only)Digital-Instant Messaging/TextingRemote-Detailing with Rep(Online)Digital-Detailing(Automated,Self guided)Digital-Meetings/Events(Prerecorded,Streaming)Digital-E-MailingMailing(Postal)Source:IQVIA Global ChannelDynamicsNote:YTD data is till July for 2019,2020,2021,2022 and 202360Germany:Full

201、 year 2019 vs.2020 vs.2021 vs.2022 and year-to-date trends over 5-yearsChannelDynamics:Channel volume and performance trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202325%23%22%24%22%29%29%29%27%29%46%48%49%49%48%YTD 2019YTD 2020YTD 2021YTD 2022YTD 2023DetractorsPromotersPassivesNPS Cat

202、egoryshare41%36%36%37%36%59%64%64%63%64%YTD 2022YTD 2023YTD 2020YTD 2019YTD 2021Converted CallsNon Converted CallsConvertedCalls1%1%20201%54%20%16%1%0%1%33%3%1%1%22%0%202124%0%1%1%0%2%20221%0%1%0%11%1%53%1%53%20%20190%19%56%1%57.9 M59.5 M62.7 M53.4 M3%+3%+5%-15%20%0%YTD Jul202014%0%4%1%1%1%0%1%1%1%0

203、%24%0%2%YTD Jul20210%1%1%0%22%0%21%1%10%1%31.0 M0%34%1%1%YTD Jul20220%53%26%1%49%YTD Jul20230%0%19%0%56%53%YTD Jul201919%1%3%55%33.2 M34.8 M36.9 M30.5 M1%+5%+6%-16%-2%F2F-Detailing with RepRemote-Detailing with Rep(Online)F2F-Meetings/EventsRemote-Meetings/Events(Live,Streaming)Mailing(Postal)Remote

204、-Detailing with Rep(Telephone,voice only)Digital-Detailing(Automated,Self guided)Digital-Meetings/Events(Prerecorded,Streaming)Digital-E-MailingDigital-Instant Messaging/TextingSource:IQVIA Global ChannelDynamicsNote:YTD data is till July for 2019,2020,2021,2022 and 2023Share of projected promotiona

205、l volume61Spain:Full year 2019 vs.2020 vs.2021 vs.2022 and year-to-date trends over 5-yearsChannelDynamics:Channel volume and performance trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202336%37%39%41%49%42%40%40%39%36%22%23%21%20%15%YTD 2019YTD 2020YTD 2021YTD 2023YTD 2022PromotersPassi

206、vesDetractorsNPS Categoryshare60%53%56%58%57%40%47%44%42%43%YTD 2021YTD 2019YTD 2020YTD 2022YTD 2023Non Converted CallsConverted CallsConvertedCalls1%14%201915%1%4%0%18%8%13%1%1%1%2020202155%1%1%0%13%1%31.2 M7%6%0%0%1%85%0%67%0%0%5%20222%4%2%45%2%0%4%10%26.6 M28.5 M28.1 M14%-15%+7%-1%1%10%50%YTD Jul

207、201949%67%1%17%2%0%YTD Jul20201%0%14%0%6%0%18.9 M1%7%15%1%0%14%YTD Jul20215%5%0%86%1%1%69%17.0 M1%6%1%0%3%13%0%0%16%1%0%YTD Jul20234%1%12%4%2%0%YTD Jul20224%8%15.5 M16.9 M17.0 M-18%+9%0%0%Remote-Meetings/Events(Live,Streaming)F2F-Detailing with RepRemote-Detailing with Rep(Online)Digital-Instant Mes

208、saging/TextingF2F-Meetings/EventsRemote-Detailing with Rep(Telephone,voice only)Digital-Detailing(Automated,Self guided)Digital-Meetings/Events(Prerecorded,Streaming)Digital-E-MailingMailing(Postal)Source:IQVIA Global ChannelDynamicsNote:YTD data is till July for 2019,2020,2021,2022 and 2023Share of

209、 projected promotional volume62France:Full year 2019 vs.2020 vs.2021 vs.2022 and year-to-date trends over 5-yearsChannelDynamics:Channel volume and performance trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202324%22%22%21%23%37%34%35%34%40%38%44%43%45%37%YTD 2023YTD 2020YTD 2019YTD 2021

210、YTD 2022PromotersPassivesDetractorsNPS Categoryshare47%40%42%40%44%53%60%58%60%56%YTD 2021YTD 2022YTD 2019YTD 2023YTD 2020Converted CallsNon Converted CallsConvertedCalls2%55%2%4%20200%8%0%0%29%46%12%201944%1%3%1%0%0%1%0%0%24.7 M46%0%11%202142%39%1%0%0%1%20229%1%1%1%0%1%2%37%29.0 M29.3 M29.6 M+1%+1%

211、-17%0%0%56%45%2%2%0%0%0%1%YTD Jul20190%0%12.1 M27%12%35%1%YTD Jul20204%42%2%1%11%2%1%1%41%0%0%0%8%YTD Jul202248%2%3%43%1%10%0%YTD Jul202138%0%9%YTD Jul20232%47%1%0%1%0%17.4 M16.3 M18.0 M15.0 M-7%+10%-16%-19%Remote-Meetings/Events(Live,Streaming)F2F-Detailing with RepF2F-Meetings/EventsRemote-Detaili

212、ng with Rep(Online)Remote-Detailing with Rep(Telephone,voice only)Mailing(Postal)Digital-Detailing(Automated,Self guided)Digital-Meetings/Events(Prerecorded,Streaming)Digital-E-MailingDigital-Instant Messaging/TextingSource:IQVIA Global ChannelDynamicsNote:YTD data is till July for 2019,2020,2021,20

213、22 and 2023Share of projected promotional volume63UK:Full year 2019 vs.2020 vs.2021 vs.2022 and year-to-date trends over 5-yearsChannelDynamics:Channel volume and performance trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202321%20%22%23%24%38%38%37%37%39%41%42%41%40%37%YTD 2021YTD 2019Y

214、TD 2020YTD 2022YTD 2023PromotersPassivesDetractorsNPS Categoryshare45%42%43%45%44%55%58%57%55%56%YTD 2023YTD 2021YTD 2019YTD 2020YTD 2022Converted CallsNon Converted CallsConvertedCalls2%28%24%3%0%0%33%35%1%3%0%0%1%20196%1%1%5%4%5%53%1%1%20210%8%26%2%4%4%0%2%52%1%2022202047%2%3%33%2%21.3 M21.7 M22.8

215、 M 22.7 M2%+2%+5%0%0%52%0%2%8%3%3%26%5%2%1%4%0%31%3%0%36%YTD Jul20199%5%1%44%YTD Jul20210%2%53%1%25%YTD Jul202211%3%3%1%28%1%0%6%2%54%1%22%YTD Jul202312.1 M4%1%3%YTD Jul20201%35%1%1%0%1%2%12.0 M13.0 M13.3 M13.1 M0%+8%+2%-2%F2F-Detailing with RepRemote-Detailing with Rep(Online)Remote-Meetings/Events

216、(Live,Streaming)F2F-Meetings/EventsRemote-Detailing with Rep(Telephone,voice only)Digital-Detailing(Automated,Self guided)Digital-Meetings/Events(Prerecorded,Streaming)Digital-E-MailingDigital-Instant Messaging/TextingMailing(Postal)Source:IQVIA Global ChannelDynamicsNote:YTD data is till July for 2

217、019,2020,2021,2022 and 2023Share of projected promotional volume64Appendix:Data Sources and Methodology65Global adult vaccination trends(Slide 5)Sources from secondary data research Slide 5 IQVIA Institute Report 2023 EIA2030 Vaccines Europe 2022 The Adult Immunization Board 2023Please note:IQVIA is

218、 not accountable for the accuracy of information from external data sourcesIQVIA Quarterly Pharmaceutical Market Outlook-August 202366IQVIA Sales Data Offerings Used and Methodology(1/2)Data sourceFrequencyData source descriptionGeographic scope of data used in this reportMeasures used for analysisC

219、alculations appliedSell-out Data(IQVIA MIDAS,IQVIA CH Customized Insights)MonthlyDetails on sales of products dispensed at retail pharmaciesThis includes both prescription and non-prescription productsPrescription products are classified using ATC classificationConsumer health products cover product

220、s from OTC,PAC,PEC and NTRItaly:Rx and CH marketsGermany:Rx and CH marketsSpain:Rx and CH marketsFrance:Rx and CH marketsItaly:UnitsGermany:UnitsSpain:UnitsFrance:UnitsItaly,Germany,Spain,France:Units Growth Jan 2023 vs.2022 To provide base view of the market from pre COVID-19 period(2019)in the yea

221、rs 2020,2021 and 2022Units Growth Latest month 2023vs.2022 To provide the latest trend in the market to understand the dynamic changes in trendsUnits Growth YTD 2023 vs.2022 To provide the YTD trend in the market to understand the long-term changes in trendsSell-in Data(IQVIA MIDAS,IQVIA CH Customiz

222、ed Insights)MonthlyDetails on sales of products dispensed at retail pharmaciesThis includes both prescription and non-prescription productsPrescription products are classified using ATC classification.Consumer health products covers products from only OTC segmentUK:Rx and CH marketsUK:UnitsUK:Units

223、Growth Jan 2023 vs.2022 To provide base view of the market from pre COVID-19 period(2019)in the year 2020,2021 and 2022Units Growth Latest month 2023 vs.2022 To provide the latest trend in the market to understand the dynamic changes in trendsUnits Growth YTD 2023 vs.2022 To provide the YTD trend in

224、 the market to understand the long-term changes in trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202367IQVIA Sales Data Offerings Used and Methodology(2/2)Data sourceFrequencyData source descriptionGeographic scope of data used in this reportMeasures used for analysisCalculations applie

225、dIQVIA MIDAS DataMonthlyDetails on hospital panel retail salesItaly hospital marketGermany hospital marketSpain hospital marketFrance hospital marketUK hospital marketItaly:UnitsGermany:UnitsSpain:UnitsFrance:UnitsUK:UnitsItaly,Germany,Spain,France,UK:Units Growth May 2021 to YTD 2023 To provide the

226、 latest trend in the market to understand the dynamic changes in trendsIQVIA Quarterly Pharmaceutical Market Outlook-August 202368Market definitions at ATC3 level of classification OncologyRespiratoryDiabetesVaccinesCardiovascularL1A:Alkylating agentsL1B:AntimetabolitesL1C:Plant-based antineoplastic

227、sL1D:Antineoplastic antibioticsL1F:Platinum antineoplasticsL1G:Monoclonal antibody antineoplasticsL1H:Protein kinase inhibitor antineoplasticsL1X:All other antineoplasticsL2A:Cytostatic hormonesL2B:Cyto hormone antagonistsV3C:RadiopharmaceuticalsAnti-asthma and COPD:R3A:B2-agonistsR3B:XanthinesR3C:N

228、-steroidal respiratory anti-inflammatoryR3D:CorticoidsR3E:B2-agonist and R3C combinationsR3F:B2-agonist and corticoid combinationsR3H:PDE4 inhibitors,asthma/COPDR3I:Devices asthmatic conditionsR3J:Antileukotriene anti-asthmaticsR3X:All other anti-asthma and COPD productsCough,cold including Flu anti

229、-virals:R5A:Cold preparationsR5B:Cough/cold preparations with anti-infectivesR5C:ExpectorantsR5D:AntitussivesR5F:Other cough and cold preparationsR4A:Chest rubs and other inhalantsR2A:Throat preparationsJ5B:Antivirals,otherA10C:Human insulin+analoguesA10D:Animal insulinA10H:Sulphonylurea antidiabeti

230、csA10J:Biguanide antidiabeticsA10K:Glitazone antidiabeticsA10L:Alpha-glucosidase inhibitor antidiabeticsA10M:Glinide antidiabeticsA10N:DPP-IV inhibitor antidiabeticsA10P:SGLT2 inhibitor antidiabeticsA10S:GLP-1 agonist anti-diabeticsA10X:Other drugs for diabetesH4B:GlucagonJ7B:Combination of vaccines

231、J7D:Bacterial vaccinesJ7E:Viral vaccinesJ7X:All other vaccine-like productsAntihypertensives:C2A:Antihypertensives(of non herbal origin)plainC2B:Antihypertensives(of non herbal origin),combination with diureticsC2C:Rauwolfia alkaloids and other antihypertensives of herbal originC2D:Rauwolfia alkaloi

232、ds and other antihypertensives of herbal origin in combination with diureticsC3A:DiureticsC7A:Beta-blocking agents,plainC7B:Beta-blocking agents,combinationsC8A:Calcium antagonists,plainC8B:Calcium antagonists,combinationsC9A:ACE inhibitors,plainC9B:ACE inhibitors,combinationsC9C:Angiotensin-II anta

233、gonists,plainC9D:Angiotensin-II antagonists,combinationsC9X:Other renin-angiotensin agentsAnticoagulants:B1A:Vit K antagonistsB1B:HeparinsB1C:Platelet aggregation inhibitorsB1D:FibrinolyticsB1E:Direct thrombin inhibitorsB1F:Direct Factor XA inhibitorsB1X:Other antithrombotic agentsB2C:Proteinase inh

234、ibitorsLipid regulators:C10A:Cholesterol and triglyceride regulating preparationsC10C:Lipid regulators,in combinations with other lipid regulatorsC11A:Lipid-regulating cardiovascular multi-therapy combination productsIQVIA Quarterly Pharmaceutical Market Outlook-August 202369Market definitions at AT

235、C3 level of classification and Oral vs.IV/SCImmunologyPainL4B:Anti-Tnf ProductsM1C:Spec Antirheumatic AgentM1A:Antirheumatic N-SteroidM1B:Antirheumat Steroid CombM2A:Top A-Rheumatics&AnalgM3A:Muscle Relaxant,PeripherM5X:Oth Musculo-Skeletal PrdN2A:Narcotic AnalgesicsN2B:Non-Narcotic AnalgesicsN2C:An

236、ti-Migraine PrepsN1A:Anaesthetics GeneralN1B:Anaesthetics,LocalNFC 1CategoryA(ORAL SOLID ORDINARY)OralB(ORAL SOLID LONG-ACTING)OralD(ORAL LIQUID ORDINARY)OralE(ORAL LIQUID LONG-ACTING)OralF(PARENTERAL ORDINARY)IV/SC formulationsG(PARENTERAL LONG-ACTING)IV/SC formulationsIQVIA Quarterly Pharmaceutica

237、l Market Outlook-August 202370Channel Definitions(Slides 58-63)RemoteinteractionsFace to face interactionsF2F Detailing:Sales Rep face-to-face detailingF2F Meetings:Meetings,events,congresses,seminarsPhone Detailing:Telephone communication with repsE-Meetings:Streaming video live webinar or pre-reco

238、rded webcastEmail:Opened email communicationE-Detailing:Online presentations live with a rep or automated,self guidedPostal:Opened paper mail received by postIQVIA Quarterly Pharmaceutical Market Outlook-August 2023712023 Channel Preference:aggregated interaction and channel groupings(slides 21-34)G

239、rouped channelOptions in surveyInteractionIndividual InteractionsFace-to-face,one-to-one sales representative visitsF2F interactiveOne-to-one telephone call with a live sales representative(audio only,without an internet presentation)Remote interactiveOne-to-one video call with a live sales represen

240、tative via Zoom,Teams,Skype etc.Instant messaging/texting via WhatsApp,Skype,Facebook Messenger etc.Meetings/Events/SeminarsAttendance at on-site/live,in-person medical conferences,group meetings,symposia,congresses etc.F2F interactiveRemote,live streaming medical conferences,group meetings,symposia

241、 etc.Remote interactiveOnline resourcesEmailsNon-interactivePodcasts(2023)On-demand online access to self-guided or automated online presentations and reference resourcesOnline information resources such as websites and mobile apps(2021,2022)OtherPostal mailingOther(Please specify)OthersSource:EMEA

242、Thought Leadership;IQVIA ChannelDynamicsChannel Preference Survey July 2023IQVIA Quarterly Pharmaceutical Market Outlook-August 2023722023 Channel Preference:Number of HCP responses(slides 21-34)Countries/RegionsNumber of responsesGermany1102EU4&UK8,838France1597Italy3419Spain1751UK969Nordics371Rest of Europe2,331US1,845APAC7,443LATAM1,737Rest of World688Grand total(38 countries)23,253IQVIA Quarterly Pharmaceutical Market Outlook-August 2023Thank You